P2X(1) receptor blockade inhibits whole kidney autoregulation of renal blood flow in vivo

Am J Physiol Renal Physiol. 2010 Jun;298(6):F1360-8. doi: 10.1152/ajprenal.00016.2010. Epub 2010 Mar 24.

Abstract

In vitro experiments demonstrate that P2X(1) receptor activation is important for normal afferent arteriolar autoregulatory behavior, but direct in vivo evidence for this relationship occurring in the whole kidney is unavailable. Experiments were performed to test the hypothesis that P2X(1) receptors are important for autoregulation of whole kidney blood flow. Renal blood flow (RBF) was measured in anesthetized male Sprague-Dawley rats before and during P2 receptor blockade with PPADS, P2X(1) receptor blockade with IP5I, or A(1) receptor blockade with DPCPX. Both P2X(1) and A(1) receptor stimulation with alpha,beta-methylene ATP and CPA, respectively, caused dose-dependent decreases in RBF. Administration of either PPADS or IP5I significantly blocked P2X(1) receptor stimulation. Likewise, administration of DPCPX significantly blocked A(1) receptor activation to CPA. Autoregulatory behavior was assessed by measuring RBF responses to reductions in renal perfusion pressure. In vehicle-infused rats, as pressure was decreased from 120 to 100 mmHg, there was no decrease in RBF. However, in either PPADS- or IP5I-infused rats, each decrease in pressure resulted in a significant decrease in RBF, demonstrating loss of autoregulatory ability. In DPCPX-infused rats, reductions in pressure did not cause significant reductions in RBF over the pressure range of 100-120 mmHg, but the autoregulatory curve tended to be steeper than vehicle-infused rats over the range of 80-100 mmHg, suggesting that A(1) receptors may influence RBF at lower pressures. These findings are consistent with in vitro data from afferent arterioles and support the hypothesis that P2X(1) receptor activation is important for whole kidney autoregulation in vivo.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / analogs & derivatives
  • Adenosine / pharmacology
  • Adenosine A1 Receptor Agonists
  • Adenosine A1 Receptor Antagonists
  • Adenosine Triphosphate / analogs & derivatives
  • Adenosine Triphosphate / pharmacology
  • Animals
  • Arterioles / drug effects
  • Arterioles / metabolism
  • Blood Pressure / drug effects
  • Dinucleoside Phosphates / pharmacology*
  • Dose-Response Relationship, Drug
  • Homeostasis
  • Kidney / blood supply*
  • Male
  • Purinergic P2 Receptor Agonists
  • Purinergic P2 Receptor Antagonists*
  • Pyridoxal Phosphate / analogs & derivatives*
  • Pyridoxal Phosphate / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Adenosine A1 / metabolism
  • Receptors, Purinergic P2 / metabolism
  • Receptors, Purinergic P2X
  • Renal Circulation / drug effects*
  • Xanthines / pharmacology*

Substances

  • Adenosine A1 Receptor Agonists
  • Adenosine A1 Receptor Antagonists
  • Dinucleoside Phosphates
  • Purinergic P2 Receptor Agonists
  • Purinergic P2 Receptor Antagonists
  • Receptor, Adenosine A1
  • Receptors, Purinergic P2
  • Receptors, Purinergic P2X
  • Xanthines
  • diinosine pentaphosphate
  • pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid
  • N(6)-cyclopentyladenosine
  • Pyridoxal Phosphate
  • Adenosine Triphosphate
  • 1,3-dipropyl-8-cyclopentylxanthine
  • Adenosine
  • alpha,beta-methyleneadenosine 5'-triphosphate